Farmas USA

ACTC

Mira de donde van a sacar las pelas, pequeña dilución al canto.

http://seekingalpha.com/news/1789013-advanced-cell-settles-warrant-lawsuit?uprof=46

S2

ACTC

Sí, han sacado un 8K. El foro se lo ha tomado a bien. Era algo esperado y hoy están optimistas con las otras noticias.

Edward Myles, ACT’s Interim President, Chief Operating Officer and Chief Financial Officer commented, “We believe the resolution of this litigation removes uncertainty from the Company's capital structure and represents a significant step toward our objective of listing on a National Exchange. Furthermore, resolution of this matter now, allows us to avoid significant additional legal expenses.”

Lawsuit Settlement

On June 4, 2014, Advanced Cell Technology, Inc. (the “Company”) entered into a settlement agreement (the “Settlement Agreement”) with each of Gary D. Aronson (“Aronson”), John S. Gorton, individually and as trustee of the John S. Gorton Separate Property Trust dated March 3, 1993 (“Gorton”), herronlaw apc, attorneys for Aronson (“Herron”), Miller and Steele LLP, attorneys for Gorton (“Miller/Steele”) and Michael A. Bourke, attorney for both Aronson and Gorton (“Bourke”). The Settlement Agreement relates to previously disclosed lawsuits filed against the Company by each of Aronson and Gorton in August 2011 in the United States District Court for the District of Massachusetts claiming that the Company breached an anti-dilution provision contained in warrants held by each of Aronson and Gorton as a result of certain transactions between the Company and other third-party investors.

Pursuant to the Settlement Agreement, in exchange for dismissal by Aronson and Gorton of the pending and non-consolidated lawsuit with prejudice within five business days of the execution of the Settlement Agreement and a mutual release of claims, the Company agreed that it would, within the five business days following the effective date of the Settlement Agreement:

· Issue to Aronson 269,766,667 shares of the Company’s common stock;

· Issue to Gorton 33,133,333 shares of the Company’s common stock; and

· Issue 68,266,667 shares of the Company’s common stock to Herron, 8,533,333 shares of the Company’s common stock to Miller/Steele, and 4,300,000 shares of the Company’s common stock to Bourke, in each case as payment in full satisfaction of any purported obligation on the part of the Company to pay any legal fees incurred by each of Aronson and Gorton in connection with their respective enforcement of the terms of their warrants.

In addition, Aronson and Gorton have each agreed to a one-year standstill provision that prevents Aronson and Gorton from the following, subject to certain exceptions: acquiring, seeking to acquire or causing to be acquired the Company’s assets or securities; soliciting proxies in an attempt to influence the voting of the Company’s securities by other holders; forming a group with other third parties for the purposes of voting the Company’s securities; arranging or proposing an acquisition of the Company’s securities or assets; otherwise proposing a merger or similar business combination transaction; announcing or disclosing an intention to undertake any of the foregoing; or assisting or encouraging others to do any of the foregoing.

The foregoing description of the Settlement Agreement is qualified in its entirety by reference to the full text of the Settlement Agreement, which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

Pedid y se os dará.

NVAX, leo lo siguiente por los comentarios de yahoo:

"briefingDOTcom is not an official source. If the pricing had been done there would be a filing at the SEC website and there is not. The clear conclusion is that it has not really been priced yet. SOMEONE somewhere jumped the gun or just posted a rumor and others bought into it.

Websites who's business is based on getting it early are prone to jumping the gun sometimes. No one has yet posted an authoritative source for the supposed pricing."

¿es correcto o se lo saca de la manga?

Garion, este es el correo que recibido de la propia NOVAVAX a las 2:57h AM ( hora española )

------------------------------------------------------------------------------------

 

GAITHERSBURG, Md., June 5, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it has priced an underwritten public offering of 25 million shares of common stock at a price to the public of $4.00 per share for gross proceeds of approximately $100 million. Novavax expects to receive net proceeds, after deducting the underwriting discount, of approximately $94 million from the offering. In connection with this offering, Novavax expects to grant to the underwriters a 30-day option to purchase up to an additional 3.75 million shares of its common stock. If the underwriters exercise this option in full, Novavax will have offered 28.75 million shares of its common stock.

Novavax intends to use the net proceeds from the offering for general corporate purposes, the advancement of its clinical-stage vaccine candidates and its pre-clinical research programs, manufacturing and process development activities, capital expenditures and other strategic purposes. The offering is expected to close on or about June 11, 2014, subject to the satisfaction of customary closing conditions.

Citigroup and JP Morgan are acting as joint book-running managers of the offering. Piper Jaffray & Co. will act as Lead Manager and FBR and Ladenburg Thalmann & Co. Inc. as Co-Managers.

A preliminary prospectus supplement and the prospectus relating to the proposed offering has been filed with the SEC. The offering may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the final prospectus supplement and the prospectus relating to the proposed offering can be obtained at the SEC's website http://www.sec.gov or from Citigroup and JP Morgan, Attention: Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.

Forward-Looking Statements

Statements contained in this release, including those relating to the expected closing of the offering, and those statements using words such as "expects" and "intends" are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully complete the offering on terms and conditions satisfactory to us; the possible adverse impact on the market price of our shares of common stock due to the dilutive effect of the securities to be sold in the offering; capital market risks; our ability to raise additional capital when needed; and other risk factors identified from time to time in the reports we file with Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which are available at www.sec.gov. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

 CONTACT: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000

Source: Novavax, Inc.

 

gracias Framus, no hay duda alguna.

Perdona framus, pero si lo envía la propia novavax (que no digo que no eh!), porqué quién distribuye la noticia es GLOBE NEWSWIRE? Si es un comunicado oficial, entiendo que no debería aparecer ninguna agencia de noticias firmando el documento.

Si lo comparas con las demás noticias, verás que nunca aparece una agencia de noticias en la propia noticia.
Bueno, no las he comprobado todas, pero unas 8 o así sí, y en ninguna aparece...

http://www.novavax.com/go.cfm?do=Press.List&Year=2014

Edito: Vale, sí que aparece Global Newswire en las más antiguas. No he dicho nada!

NVAX no tiene departamento de marketing. quizas usen a terceros.
de todas maneras, llevo recibiendo mails de la compañia desde que me registre, claro esta, y no he notado nada que me hiciera ver que la procedencia no era legitima,

una cosa. si vas a la newsroom de NVAX, La new de hoy de la dilucion aparece el link roto, seran chapuzas ....

NVAX